Skip to main content
John Sundy, MD, Rheumatology, Foster City, CA

JohnSundyMDPhD

Rheumatology Foster City, CA

Crystal Related, Rheumatoid Arthritis & Related, Clinical Pharmacology

Senior Vice President Clinical Research Gilead Sciences

Dr. Sundy is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Sundy's full profile

Already have an account?

Education & Training

  • Duke University Hospital
    Duke University HospitalFellowship, Allergy and Immunology, 1995 - 1996
  • Duke University Hospital
    Duke University HospitalFellowship, Rheumatology, 1994 - 1995
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 1991 - 1994
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 1991, MD, PhD

Certifications & Licensure

  • NC State Medical License
    NC State Medical License 1994 - 2024
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2014
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
  • Fellow (FAAAAI) American Academy of Allergy Asthma and Immunology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • The Drug Company That Prospered Without Creating Any Drugs
    The Drug Company That Prospered Without Creating Any DrugsApril 13th, 2023
  • Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease Trial
    Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease TrialJanuary 4th, 2021
  • Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 Was Well-Tolerated and Selectively Expanded Regulatory T Cells
    Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 Was Well-Tolerated and Selectively Expanded Regulatory T CellsJanuary 4th, 2021
  • Join now to see all

Professional Memberships